PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast
- Education
- Health & Fitness · Medicine
- Science
Free on the App Store for iPhone, iPad and Mac. No subscription needed. Once it is installed, tap this link again and the show is yours. Already have it? Open in Parasocial.
About
PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it...
Also on
Recent episodes
- Lynsey P. Teulings, APRN - Taking the Leap Forward in HNSCC: Nurses at the Forefront of Delivering Modern Immunotherapy and Preparing for Bispecifics in LA and R/M Disease
- Yelena Y. Janjigian, MD* / Siva Raja, MD, PhD, FACS - Redefining Perioperative Care in Resectable Gastric/GEJ Cancer: Practical Guidance on Delivering Surgical and Immunotherapy Interventions for Superior Outcomes
- Thomas Martin, MD / Amrita Krishnan, MD, FACP - Personalizing Multiple Myeloma Care: Evidence and Guideline-Informed Application of Current Treatment Options
- Amy Brownlee, MD / Elena Elimova, MD, MSc, FRCPC - Cracking the HER2 Code in GI Cancers: Evidence, Guidelines, and Targeted Interventions in GEA and BTC
- Ghassan Abou-Alfa, MD, JD, MBA, PhD(hc) - Redefining Therapeutic Progress in HCC: Extending the Benefits of Immunotherapy to Earlier Stages of Disease
- Erika Hamilton, MD / Tiffany A. Traina, MD, FASCO - Practice Readiness for TROP2-Targeting ADCs in First-Line TNBC: Right Patient, Right Time, Right Team
- Stephen V. Liu, MD - Building a Better Backbone for NSCLC and SCLC Treatment With PD-(L)1xVEGF-A Bispecific Antibodies: Inducing Immune Invigoration, Simplifying Treatment Delivery, and Enhancing Clinical Outcomes
- Prof. David Planchard, MD, PhD - From Data to Decisions in HER2-Overexpressing NSCLC: Detecting Alterations, Implementing Therapeutic Advances, and Navigating Practicalities of Care
- Nikhil I. Khushalani, MD - The Next Act of Immunotherapy in CSCC: Upgrading the Risk-Adapted Management of Resectable Disease
- William G. Wierda, MD, PhD - C3–Changing Conversations on CLL: Evidence and Emerging Consensus on Targeted Agents Across Lines of Therapy